The Phase 3 study found a drug didn’t reduce the risk of cardiovascular events like heart attacks and strokes.
Source link
About The Author
A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study